Skip to main content
. 2022 Dec 9;22:536. doi: 10.1186/s12872-022-02956-4

Table 3.

Hazard Ratios and 95% Confidence Interval for CHD and CVD According to Continuous CAC Density and CAC Density Quartile

DM
(n = 668)
MetS
(n = 1122)
Neither DM/MetS
(n = 2028)
CHD
N (%) of events 161 (24.1%) 203 (18.1%) 276 (13.6%)
Per 1 SD of CAC density 0.91 (0.72–1.16) 0.70 (0.56–0.87)† 0.79 (0.66–0.95)*
CAC density Q2 versus Q1 0.79 (0.44–1.41) 0.88 (0.53–1.46) 0.93 (0.60–1.44)
CAC density Q3 versus Q1 0.79 (0.43–1.46) 0.67 (0.38–1.20) 0.56 (0.35–0.92)*
CAC density Q4 versus Q1 0.89 (0.47–1.67) 0.50 (0.28–0.91)* 0.59 (0.36–0.97)*
CVD
N (%) of events 248 (37.1%) 308 (27.5%) 433 (21.4%)
Per 1 SD of CAC Density 0.77 (0.64–0.94)† 0.83 (0.70–0.99)* 0.82 (0.71–0.95)†
CAC density Q2 versus Q1 0.71 (0.45–1.10) 1.04 (0.70–1.56) 0.81 (0.58–1.12)
CAC density Q3 versus Q1 0.62 (0.38-1.00)* 1.04 (0.66–1.64) 0.53 (0.37–0.78)†
CAC density Q4 versus Q1 0.54 (0.32–0.89)* 0.67 (0.41–1.08) 0.59 (0.41–0.86)†

Models were adjusted for 10-year ASCVD risk, race/ethnicity, education, BMI, statin therapy and ln(Volume)

ASCVD  Atherosclerotic cardiovascular disease, BMI  Body mass index, CAC Coronary artery calcium, CHD Coronary heart disease, CVD  Cardiovascular disease, DM  diabetes mellitus, MetS  metabolic syndrome

*p < 0.05, †p < 0.01